Premier of South Australia Steven Marshall Briefed on $50 billion Clinical Trial Sector During Visit to Adelaide-based Avance Clinical
June 1, 2020
The leading Australian CRO for biotechs, Avance Clinical, hosted a visit with the Premier of South Australia the Hon. Steven Marshall MP to discuss the fast-growing clinical trials sector, currently worth $50 billion and increasing to $71.7 billion by 2024 according to Frost & Sullivan.
Avance Clinical manages biotech clinical trials in Australia, from its
headquarters in South Australia, working with hundreds of clinics and research
teams around the country to assess new drugs for regulatory approval that could
make a real difference to people’s lives.
The Premier toured the facility in Thebarton and took a briefing on the
sector from Avance CEO Yvonne Lungershausen and her team.
Avance Clinical CEO Yvonne Lungershausen said:
“Most of Avance
Clinical’s biotech clients are from the USA while numbers from the EU and Asia
are on the increase, particularly from China and South Korea.
Australia is a
well-established location for international clinical trials and our management
of the COVID-19 crisis has made it an even more attractive trials destination.
has managed the COVID-19 pandemic extremely well, allowing Avance Clinical to continue
operations throughout the crisis. However, in other countries clinical trials
have been suspended or closed, putting extreme pressure on the biotech sector.”
There are currently 764 clinical studies underway or planned in South
Australia alone and a total of 2,225 in Australia.” (ClinicalTrials.Gov)
Avance Clinical is a medium-sized full-service CRO known for its nimble
and collaborative approach, with more than 20-years of experience in managing
early phase trials.
In addition to the impressive COVID-19 management, a key factor in sponsor
demand is the speed, and attractive cost of running trials in Australia
Australian Government financial rebate of more than 40% on clinical trial
No IND required for clinical trials and
streamlined regulatory processes
Advanced medical, research and scientific
community, leading investigators and KOLs, and modern medical facilities
Australia’s reputation for FDA compliant scientific and research
excellence, its advanced healthcare, and the opportunity to access patients in
a less clinical trial competitive environment further reinforces its advantage
as a destination for clinical trials.
Adelaide-based Avance Clinical has more than 20-years of experience
and is now one of Australia’s leading Contract Research Organisations. Avance
Clinical facilitates quality drug development by aligning people, skills, and
expertise in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality
clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance
Clinical continually grows through the careful selection of experts who also
demonstrate passion in their chosen field.
Avance Clinical offers high quality services in an
established clinical trial ecosystem, that includes world-class Investigators
and Sites able to access specialised patient groups. Other benefits include:
The Government R&D grant means more than 40%
rebate on clinical trial spend
Telehealth pivot during COVID-19 pandemic – speed
Site Initiation Visit (SIV) and Study Start
achieved in 5 – 6 weeks
No IND required for clinical trials
Full GMP material is not mandated for Phase I
Established clinical trial environment with
world-class Investigators and sites
Established healthy subject databases and specialised
Five independent Phase 1 facilities across
Australia including hospital-based units for critical care
Major hospitals with world class infrastructures
and dedicated Clinical Trial Units with a long track-record in FDA
Seasonal studies: Northern hemisphere Sponsors
can conduct their studies year-round by taking advantage
of Australia’s counter-flu and allergy seasons